Peripheral blood stem cell (PBSC) mobilization with chemotherapy followed by sequential IL-3 and G-CSF administration in extensively pretreated patients

Bone Marrow Transplantation

Volumn 20, Issue 12, 1997, Pages 1027-1032

  Kolbe, K ^a   Peschel, C ^a   Rupilius, B ^a   Despres D ^a   Burger, K ^b   Sklenar, I ^b   Farber L ^b   Huber, C ^a   Derigs, H G ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b Novartis AG   (Germany)

Author keywords

G CSF; IL 3; Mobilization; PBSC; Transplantation

Indexed keywords

ANTINEOPLASTIC AGENT; CD34 ANTIGEN; INTERLEUKIN 3; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; BONE MARROW TOXICITY; BONE PAIN; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HODGKIN DISEASE; HUMAN; HUMAN CELL; MALE; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NEUTROPHIL; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RISK FACTOR; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION; TESTIS CANCER;

EID: 0031450724     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701019     Document Type: Article

References (19)

1. Elias AD, Ayash L, Anderson KC et al. Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood 1992; 79: 3036-3044.
2. Peters WP, Rosner G, Ross M et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709-1719.
3. Brugger W, Bross KJ, Glatt M et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636-640.
4. Dreger P, Kloss M, Petersen B et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood 1995; 86: 3970-3978.
5. Weaver CH, Hazelton B, Birch R et al. An analysis of engraftement kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995; 86: 3961-3969.
6. Shimazaki C, Yamagata N, Tatsumi T et al. Mobilization of peripheral blood progenitor cells by high-dose Ara C, VP-16 and recombinant human granulocyte colony-stimulating factor: factors affecting progenitor cell yields. Bone Marrow Transplant 1995; 15: 763-767.
7. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-2555.
8. Passos Coelho JL, Braine HG, Davis JM et al. Predictive factors for peripheral-blood progenitor-cell collections using a single large-volume leukapheresis after cyclophosphamide and granulocyte-macrophage colony-stimulating factor mobilization. J Clin Oncol 1995; 13: 705-714.
9. Haas R, Mohle R, Fruhauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1994; 83: 3787-3794.
10. Ohi S, Sakamaki S, Matsunaga T et al. Co-administration of IL3 with G-CSF increases the CFU-S mobilization into peripheral blood, Int J Hematol 1995; 62: 75-82.
11. Geissler K, Peschel C, Niederwieser D et al. Potentiation of granulocyte colony-stimulating factor-induced mobilization of circulating progenitor cells by seven-day pretreatment with interleukin-3. Blood 1996, 87: 2732-2739.
12. D'Hondt V, Guillaume T, Humblet Y et al. Tolerance of sequential or simultaneous administration of IL-3 and G-CSF in improving peripheral blood stem cells harvesting following multi-agent chemotherapy: a pilot study. Bone Marrow Transplant 1994; 13: 261-264.
13. Peschel C, Paul W, Ohara J, Green I. Effects of B cell stimulatory factor 1/interleukin-4 on hemopoietic progenitor cells. Blood 1987; 70: 254-261.
14. Nemunaitis J. Cytokine-mobilized peripheral blood progenitor cells. Semin Oncol 1996; 23: 9-14.
15. Geissler K, Peschel C, Niederwieser D et al. Effect of interleukin-3 pretreatment on granulocyte/macrophage colony-stimulating factor induced mobilization of circulating haemopoietic progenitor cells. Br J Haematol 1995; 91: 299-305.
16. Brugger W, Bross K, Frisch J et al. Mobilization of peripheral blood progenitor cells by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide, and cisplatin (see comments). Blood 1992; 79: 1193-1200.
17. Brugger W, Frisch J, Schulz G et al. Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following standard-dose combination chemotherapy with etoposide, ifosfamide, and cisplatin. J Clin Oncol 1992; 10: 1452-1459.
18. Winter JN, Lazarus H, Rademaker A et al. Phase I/II study of combined granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor administration for the mobilization of hematopoietic progenitor cells. J Clin Oncol 1996; 14: 277-286.
19. Moskowitz C, Stiff P, Gordon M et al. The influence of extensive prior chemotherapy on the mobilization of peripheral blood progenitor cells (PBPC) using stem cell factor (rhSCF) and filgrastim (rmetHuG-CSF) on hematologic recovery post cyclophosphamide, BCNU, and VP-16 (CBV) in patients with relapsed non-Hodgkin's lymphoma (NHL): an interim analysis. Blood 1994; 84 (Suppl. 1): 107 (Abstr.).